A "Window Trial" on Boswellia for Breast Cancer Primary Tumors

Phase 1 Completed 46 enrolled Medical University of South Carolina

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether oral administration of Boswellia causes biological changes in primary tumors of breast cancer patients.

Timeline

Start: 2017-08-31
Primary completion: 2024-04-29
Completion: 2024-04-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Boswellia	Traditional medicine (herbal / TCM)	800 mg	Oral

A "Window Trial" on Boswellia for Breast Cancer Primary Tumors

Summary

Timeline

Drugs

Indications